Initial Seed Financing Secured August 21, 2007 • admin • Funding, Pharmaceuticals Following the incorporation of the company, Countervail was able to secure its initial seed funding from an Austrian pharmaceutical company that synthetically manufactures galantamine which is the company’s initial drug under development. Related News Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. May 29, 2015 Countervail Corporation presents significant results of i.m. dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held in Denver Colorado. June 7, 2014